Operational Update
12 June 2025
Vast Resources plc
('Vast' or the 'Company')
Operational Update
Vast Resources plc, the AIM quoted mining company, is pleased to announce that it has established a group technical services function including the input of experienced mining engineers, geologists and operations management which will be tasked with undertaking a review of Vast's existing asset base. The focus will be to establish a sustainable operational plan that will subsequently support ongoing technical studies aimed at unlocking the potential of the current asset base as well as assessing new potential opportunities in Romania, Tajikistan and Zimbabwe.
Overview Very encouraging initial indications of diamond quality following preliminary cleaning of a representative of parcel of stones.
Initial diamond sales, by way of public or private tender in Dubai, are expected to commence in the coming weeks.
Comprehensive technical review of the Romanian assets focussing on the Baita Plai Mine in Romania in Q3 2025 with the objective of establishing the optimal mining strategy.
This plan will likely include the development a new drilling programme and mine plan designed to grow and increase the confidence of the current JORC Resource and Reserve base.
The technical review will also consider the opportunity to restart activities at the Manaila-Carlibaba Copper Mine in Romania during H2 2025.
Andrew Prelea, CEO of Vast, commented:
'Our recent success with the return of the Historic Parcel of diamonds has sparked a comprehensive review of our asset portfolio and our strategy for becoming a mid-tier production company. Our Romanian assets, specifically Baita Plai and Manaila-Carlibaba, hold significant value for the Company. We are now working towards realising the potential of these assets through a comprehensive and diligent technical assessment of these assets, including the development of a sustainable mining plan at Baita Plai, and the opportunity of restarting mining activities at Manaila-Carlibaba. I look forward to providing updates on these processes in the coming months, along with news on the expected diamond sales in the coming weeks.'
Further Information
Update on Diamond Consignment
The Company is now undertaking initial cleaning of a representative selection of parcels of stones from the Diamond Consignment, with initial indications of quality, interpreted by industry specialists using industry standard inspections, being very encouraging and supportive of the Company's current sales and marketing strategy which involves primary beneficiation, and a phased sale of stones to maximise revenues.
Vast expects that initial diamond sales, by way of public or private tender in Dubai, will commence in a matter of weeks, and further updates on this process will be provided in due course.
Romanian Operations
One of the Company's immediate priorities is to overhaul operations at Baita Plai by undertaking a comprehensive review of the geology of the project and the mining strategy. This will include the generation of a new mine plan, supported if necessary, by a drilling programme to further inform the mining studies. To ensure that there is an optimal outcome from this review it has been deemed prudent to undertake a temporary suspension of operations, currently expected to last for up to three months. Vast's decision to commence this work is underpinned by its confidence in its ability to realise significant value from the sale of the diamonds recently returned to the Company by way of Settlement Deed. The Company also notes that this review will also include reviewing the existing plan to restart activities at its Manaila-Carlibaba project in Romania during the second half of 2025 and is in ongoing associating discussions with potential offtake partners.
**ENDS**
For further information, please visit the Company's website at www.vastplc.com or contact: Vast Resources plc
Andrew Prelea (CEO) +44 (0) 20 7846 0974 Strand Hanson Limited – Nominated & Financial Adviser
James Spinney / James Bellman +44 (0) 207 409 3494 Shore Capital Stockbrokers Limited – Joint Broker
Toby Gibbs / James Thomas (Corporate Advisory) +44 (0) 20 7408 4050 Axis Capital Markets Limited – Joint Broker
Richard Hutchinson +44 (0) 20 3206 0320 St Brides Partners Limited
Susie Geliher http://www.stbridespartners.co.uk/
+44 (0) 20 7236 1177
ABOUT VAST RESOURCES
Vast Resources plc is a United Kingdom AIM quoted mining company with mines and projects in Romania, Tajikistan, and Zimbabwe.
In Romania, the Company is focused on the rapid advancement of high-quality projects by recommencing production at previously producing mines.
The Company's Romanian portfolio includes 100% interest in Vast Baita Plai SA which owns 100% of the producing Baita Plai Polymetallic Mine, located in the Apuseni Mountains, Transylvania, an area which hosts Romania's largest polymetallic mines. The mine has a JORC compliant Reserve & Resource Report which underpins the initial mine production life of approximately 3-4 years with an in-situ total mineral resource of 15,695 tonnes copper equivalent with a further 1.8M-3M tonnes exploration target. The Company is now working on confirming an enlarged exploration target of up to 5.8M tonnes.
The Company also owns the Manaila Polymetallic Mine in Romania, which the Company is looking to bring back into production following a period of care and maintenance. The Company has also been granted the Manaila Carlibaba Extended Exploitation Licence that will allow the Company to re-examine the exploitation of the mineral resources within the larger Manaila Carlibaba licence area.
The Company retains a continued presence in Zimbabwe. The Company is re-engaging its future investment strategy in Zimbabwe and has commenced discussions with further mining concessions in-country alongside its wider portfolio.
Vast has an interest in a joint venture company which provides exposure to a near term revenue opportunity from the Takob Mine processing facility in Tajikistan. The Takob Mine opportunity, which is 100% financed, will provide Vast with a 12.25 percent royalty over all sales of non-ferrous concentrate and any other metals produced.
Also in Tajikistan, Vast has been contracted to develop and manage the Aprelevka gold mines on behalf of its owner Gulf International Minerals Ltd ('Gulf') under which Vast is entitled, inter alia, to 10% of the earnings that Gulf receives from its 49% interest in Aprelevka in joint venture with the government of Tajikistan. Aprelevka holds four active operational mining licences located along the Tien Shan Belt that extends through Central Asia, currently producing approximately 11,600oz of gold and 116,000 oz of silver per annum. It is the intention of the Company to assist in increasing Aprelevka's production from these four mines closer to the historical peak production rates of approximately 27,000oz of gold and 250,000oz of silver per year from the operational mines.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
29 minutes ago
- Business Insider
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ('CERo'), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the 'Investors') pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company's common stock. 'We welcome this vote of confidence and the continued support of our investors as we continue to show progress along our clinical timeline. The completion of our first-in-human dosing represents a significant clinical development milestone in AML for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L, and we will continue to communicate results as the data matures,' said Chris Ehrlich, Chief Executive Officer. The gross proceeds to CERo from today's closing are expected to be approximately $750,000, with up to $2.25 million of cash that may be funded at one or more additional closings, at the election of the Investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. In April 2025, CERo initiated clinical trials for its lead product candidate, CER-1236,for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Business Insider
29 minutes ago
- Business Insider
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the 'Company') announced that it received a Staff delisting letter from The Nasdaq Capital Market ('Nasdaq') on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the '10-Q') is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the 'Rule'). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'Commission') on April 24, 2025, the Company received a deficiency notice from Nasdaq that the Company was not in compliance with Nasdaq's Listing Rules as set forth in the Rule given the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the '10-K'). As previously reported in the Current Report on Form 8-K filed with the Commission on April 18, 2025, the Company received a Staff delisting letter from the Nasdaq Listing Qualifications Staff indicating that, based upon the closing bid price of the Company's common stock, par value $0.00001 per share ('Common Stock'), from November 25, 2024 to January 10, 2025, the Company was no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the 'Minimum Bid Price Rule'). On April 14, 2025, Nasdaq issued a further notice to the Company that it determined that the Company's securities had a closing bid price of $0.10 or less for ten consecutive trading days and was subject to delisting pursuant to the provisions under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As a result, unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the 'Panel'), trading of the Common Stock would be suspended at the opening of business on April 23, 2025, and a Form 25-NSE would be filed with the Commission, which would remove the Company's securities from listing and registration on Nasdaq. The Company timely requested a hearing before the Panel, which stayed the trading suspension pending the Panel's decision, and the Panel has scheduled a hearing date of May 27, 2025. As the Company is already before a Panel for its failure to comply with Minimum Bid Price Rule, the Company had seven calendar days from the date of the Notice, or until May 1, 2025, to request a stay of the suspension, which request will stay the suspension of the Company's securities pending the Panel's decision. The Company submitted a stay request on May 1, 2025. However, there can be no assurance that the Panel will grant the Company's request for a stay pending the hearing process or any further extension following the hearing. The Company intends to file the Form 10-K and 10-Q as promptly as possible in order to regain compliance with the Rule. About Onconetix, Inc.: Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Through our acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union ('EU') under the In Vitro Diagnostic Regulation ('IVDR'). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia ('BPH'), a disorder of the prostate. For more information, visit Contact Information:
Business Insider
29 minutes ago
- Business Insider
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ('Onconetix' or the 'Company'), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the 'Special Meeting') held on May 30, 2025, and that its Board of Directors (the 'Board of Directors' or 'Board') approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 13, 2025. Results of the Special Meeting At the Special Meeting, Onconetix's stockholders approved the following proposals: an amendment to the Onconetix, Inc. Amended and Restated Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-10 to 1-for-150, at any time prior to the one-year anniversary date of the Special Meeting, with such ratio to be determined by the Board without further approval or authorization of the stockholders; and the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. (the 'Adjournment Proposal'). Final voting results from the Special Meeting were reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'SEC') on June 5, 2025. In conjunction with stockholder approval of the reverse stock split, the Company's Board of Directors determined to fix a split ratio of 1-for-85 shares. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on June 13, 2025. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'ONCO' under the new CUSIP number 68237Q203. The reverse stock split is intended to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market. At the effective time of the reverse split, every 85 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be canceled with the holders thereof receiving cash compensation. The amount of compensation will be determined by multiplying the fractional share by the closing price per share of the Company's common stock on The Nasdaq Capital Market at the close of business on the trading day prior to the effective date of the reserve stock split, or June 12, 2025. The reverse split will have no effect on the number of authorized shares of the Company's common stock, and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. The reverse stock split will additionally apply to the Company's common stock issuable upon exercise or conversion of the Company's equity awards, convertible preferred stock and warrants, as well as the applicable exercise price. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 44.4 million to approximately 521,863. About Onconetix, Inc. Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation. The Company also owns ENTADFI, an FDA-approved, once-daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia, a disorder of the prostate. For more information, visit Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements (including, without limitation, statements regarding the timing and effectiveness of the anticipated reverse split and compliance with applicable Nasdaq continued listing requirements) are based on Onconetix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions; whether the Company will be able to regain and maintain compliance with Nasdaq's applicable listing criteria and the effect of a delisting from Nasdaq on the market for the Company's securities; whether a definitive agreement for the proposed transaction with Ocuvex Therapeutics, Inc. ('Ocuvex') and any related financing will be entered into; whether such transactions, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of a proposed transaction with Ocuvex; Onconetix's ability to integrate the assets and commercial operations contemplated to be acquired from Ocuvex into the Company's business; risks related to Onconetix's ability to commercialize or monetize Proclarix and integrate the assets and commercial operations; risks related to the Company's present need for capital to commercially launch Proclarix and have adequate working capital; risks related to Onconetix's ability to attract, hire and retain skilled personnel necessary to commercialize and operate the Company's commercial products; the failure to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix's products; risks related to the Company's ability to obtain and maintain intellectual property protection for its current products; and the Company's reliance on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix's Annual Report on Form 10-K, filed with the SEC on June 2, 2025 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. For more information: Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, OH 45202 Phone: (513) 620-4101
